Recombinant Human LRRK2 (N-GST tag)
Catalog No : IGX-RP897
366.40€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human LRRK2 (N-GST tag) | ||
|---|---|---|---|
| Catalog No | IGX-RP897 | ||
| Supplier’s Catalog No | IGX-RP897 | ||
| Supplier | ImuGeX | ||
| Source antigen | Insect cells | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 210 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | PARK8; RIPK7; ROCO2; AURA17; DARDARIN | ||
| Grade | Highly Purified | ||
| Purity | 70% - 90% | ||
| Form | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | 70% - 90% | ||
| Description | LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains . LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 . | ||
Product Details
© 2020 Imugex All Rights Reserved